Sravani Gundarlapalli
Researcher
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Sravani Gundarlapalli's research focuses on multiple myeloma and related stem cell transplantation outcomes. Recent publications investigate the feasibility and risk factors for outpatient stem cell transplantation in multiple myeloma patients, as well as the efficacy of salvage autologous stem cell transplantation in cases refractory to daratumumab treatment. Additional work examines the role of persistent bone marrow minimal residual disease as a prognostic indicator and explores methods for predicting progression risk in relapsed multiple myeloma using traditional models, PET-CT imaging, and minimal residual disease status. Gundarlapalli also contributes to understanding corneal toxicity associated with belantamab mafodotin. Key collaborators include Nishanth Thalambedu, Munawwar Hussain, Sharmilan Thanendrarajan, and Guido Tricot, all from the University of Arkansas for Medical Sciences, with whom Gundarlapalli has co-authored multiple publications.
Metrics
- h-index: 5
- Publications: 21
- Citations: 66
Selected Publications
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026) DOI
- Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022) DOI
- Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022) DOI
- MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022) DOI
- Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience (2022) DOI
- Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021 (2022) DOI
- Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience (2022) DOI
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022) DOI
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022) DOI
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021) DOI
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials (2021) DOI
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma (2021) DOI
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status (2021) DOI
- Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM). (2021) DOI
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021) DOI
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics